News | Novartis novartis.com

1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years

novartis.com·22w

Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS

novartis.com·24w

Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

novartis.com·24w

Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets

novartis.com·25w

Novartis announces plans to build flagship manufacturing hub in North Carolina

novartis.com·25w

Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance

novartis.com·26w

Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance

novartis.com·28w

Novartis verzeichnet im dritten Quartal solide Steigerungen beim Umsatz und operativen Kernergebnis sowie starke Fortschritte in der Pipeline; Prognose für das Geschäftsjahr 2025 bestätigt

novartis.com·28w

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

novartis.com·28w

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

novartis.com·32w

Bringing breakthroughs to more patients

novartis.com·32w

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

novartis.com·39w

Novartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch retires after 22 years with the company

novartis.com·43w

Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance

novartis.com·43w

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

novartis.com·49w

Why advocating for your MS is so important

novartis.com·51w

Vas Narasimhan named to 2025 TIME100 Health list

novartis.com·53w

Europe talks health sovereignty

novartis.com·55w

Science in Motion: Autumn and Sabrina's Noteworthy Novartis Adventure

novartis.com·56w

Parental leave

novartis.com·63w

Log in to enable infinite scrolling